GO:0010124 phenylacetate catabolic process: Aromatic Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010124 phenylacetate catabolic process describes the chemical reactions and pathways that break down phenylacetate, a key aromatic compound derived from phenylalanine.
• In bacteria, this process is best characterized in Escherichia coli and Pseudomonas species, where the paa gene cluster encodes a multi-enzyme pathway that converts phenylacetate to central metabolites.
• In humans, phenylacetate is a uremic toxin and a product of gut microbial phenylalanine metabolism; its accumulation has been linked to mitochondrial dysfunction and disease.
• The pathway is regulated by substrate availability and global regulators such as the paaX repressor in bacteria, and by host-microbiome interactions in mammals.
• Dysregulation of phenylacetate catabolism is implicated in inherited metabolic disorders, chronic kidney disease, and cancer metabolism.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of paa genes and their roles in health and disease.
Description
Phenylacetate catabolic process (GO:0010124) is the set of biochemical reactions that result in the breakdown of phenylacetate, an aromatic carboxylic acid. This process is essential for the metabolism of phenylalanine and other aromatic compounds in bacteria, and it also occurs in mammalian systems as part of host-microbiome interactions. In bacteria, the pathway allows the utilization of phenylacetate as a carbon source, converting it into intermediates of the tricarboxylic acid cycle. In humans, phenylacetate is a uremic toxin and a product of gut microbial metabolism; its catabolism is critical for maintaining metabolic homeostasis. Understanding this pathway has broad implications for microbiology, metabolic engineering, and human disease research.
phenylacetate catabolic process At A Glance
| GO ID | GO:0010124 |
|---|---|
| GO term | phenylacetate catabolic process |
| Ontology | biological_process |
| Synonym | phenylacetate breakdown; phenylacetate catabolism; phenylacetate degradation |
| Major function | Breakdown of phenylacetate into central metabolites |
| Key organisms | Bacteria (e.g., Escherichia coli, Pseudomonas), mammals (via microbiome) |
| Key genes | paaA, paaB, paaC, paaD, paaE, paaF, paaG, paaH, paaJ, paaK, paaZ |
| Associated diseases | Uremia, inherited metabolic disorders, cancer |
| Research methods | CRISPR knockout, knock-in, overexpression, metabolomics, transcriptomics |
What Is GO:0010124?
According to the Gene Ontology, GO:0010124 phenylacetate catabolic process is defined as the chemical reactions and pathways resulting in the breakdown of phenylacetate. This includes the enzymatic steps that convert phenylacetate into simpler compounds, such as acetyl-CoA and succinyl-CoA, which can enter central metabolic pathways.
Why Is phenylacetate catabolic process Important in Cell Biology?
Phenylacetate catabolic process is important because it governs the fate of an aromatic compound that is both a microbial carbon source and a human uremic toxin. In bacteria, this pathway is a model for aromatic degradation and has biotechnological applications. In humans, impaired phenylacetate clearance contributes to uremic toxicity and has been linked to mitochondrial dysfunction, making it a target for therapeutic intervention. Additionally, inherited disorders of phenylalanine metabolism, such as phenylketonuria, involve phenylacetate as a diagnostic marker, and its catabolism intersects with nitrogen scavenging therapies.
• Provides a model for bacterial aromatic compound degradation and bioremediation.
• Enables utilization of phenylacetate as a carbon source in bacteria.
• Contributes to uremic toxicity in chronic kidney disease.
• Links gut microbial metabolism to host mitochondrial function.
• Involved in nitrogen scavenging therapy for urea cycle disorders.
• Serves as a biomarker for phenylalanine metabolism disorders.
• Potential target for metabolic engineering of aromatic compounds.
• Relevant to cancer metabolism due to altered aromatic amino acid catabolism.
• Aids in understanding host-microbiome co-metabolism.
• Facilitates development of CRISPR models for gene function studies.
What Happens During phenylacetate catabolic process?
Uptake and Activation of Phenylacetate
In simple terms: The cell takes in phenylacetate and prepares it for breakdown.
In bacteria, phenylacetate is transported into the cell and activated to phenylacetyl-CoA by the enzyme phenylacetate-CoA ligase (encoded by paaF). This activation step is required for subsequent ring modification and cleavage.
Ring Hydroxylation and Cleavage
In simple terms: The aromatic ring is modified and opened.
Phenylacetyl-CoA undergoes hydroxylation and ring cleavage by a multi-enzyme complex encoded by the paa gene cluster. The paaABCDE genes form a multicomponent oxygenase that hydroxylates the ring, followed by cleavage to yield intermediates such as 2-hydroxyphenylacetyl-CoA.
Beta-Oxidation-like Steps
In simple terms: The opened ring is further processed in steps similar to fat breakdown.
The ring-cleavage product is further metabolized through beta-oxidation-like reactions, involving paaG, paaH, paaJ, and paaK, resulting in the production of acetyl-CoA and succinyl-CoA, which enter the tricarboxylic acid cycle.
Regulation of the paa Pathway
In simple terms: The pathway is turned on only when needed.
In E. coli, the paa pathway is regulated by the repressor PaaX, which binds to the promoter region and inhibits transcription in the absence of phenylacetate. Upon phenylacetate availability, PaaX is inactivated, allowing expression of the paa genes.
Mammalian and Microbiome Context
In simple terms: In humans, gut bacteria break down phenylacetate, affecting health.
In mammals, phenylacetate is produced by gut microbiota from phenylalanine and can be further metabolized by microbial enzymes. Host tissues may also catabolize phenylacetate, and its accumulation is associated with uremic toxicity.
Key Genes Involved in GO:0010124 phenylacetate catabolic process
The following genes are central to phenylacetate catabolic process, primarily identified in bacterial systems and relevant to human microbiome studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| paaA | Component of phenylacetyl-CoA oxygenase | Ring hydroxylation; knockout reduces pathway flux |
| paaB | Component of phenylacetyl-CoA oxygenase | Ring hydroxylation; essential for activity |
| paaC | Component of phenylacetyl-CoA oxygenase | Ring hydroxylation; potential target for inhibitors |
| paaD | Component of phenylacetyl-CoA oxygenase | Ring hydroxylation; structural role |
| paaE | Component of phenylacetyl-CoA oxygenase | Electron transfer; redox partner |
| paaF | Phenylacetate-CoA ligase | Activation of phenylacetate; first step |
| paaG | Ring-opening enzyme | Cleavage of aromatic ring; key step |
| paaH | Beta-oxidation-like enzyme | Processing of ring-cleavage product |
| paaJ | Beta-oxidation-like enzyme | Processing of ring-cleavage product |
| paaK | Beta-oxidation-like enzyme | Processing of ring-cleavage product |
| paaX | Transcriptional repressor | Regulates paa operon; knockout causes constitutive expression |
| paaZ | Aldehyde dehydrogenase | Final steps of phenylacetate catabolism |
| paaY | Putative thioesterase | May hydrolyze CoA intermediates |
| paaZ | Bifunctional enzyme | Ring cleavage and aldehyde oxidation |
| paaF | CoA ligase | Substrate activation; rate-limiting |
| paaG | Enoyl-CoA hydratase | Beta-oxidation-like step |
| paaH | 3-hydroxyacyl-CoA dehydrogenase | Beta-oxidation-like step |
How Is phenylacetate catabolic process Regulated?
The bacterial phenylacetate catabolic pathway is primarily regulated by the transcriptional repressor PaaX, which binds to the paa promoter and blocks transcription in the absence of phenylacetate. When phenylacetate is present, it interacts with PaaX, relieving repression and allowing expression of the paa genes. Additionally, global regulators such as cyclic AMP receptor protein (CRP) may influence expression in response to carbon source availability. In mammalian systems, phenylacetate levels are influenced by gut microbial metabolism and host clearance mechanisms, with potential regulation by SIRT3-mediated lysine phenylacetylation.
phenylacetate catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| paaF | Bacterial aromatic degradation | Knockout in E. coli to block phenylacetate utilization |
| paaX | Regulation of paa operon | Reporter assay with paaX knockout |
| SIRT3 | Mitochondrial dysfunction | Knockout mouse model for phenylacetylation |
| paaG | Ring cleavage defect | Point mutation to alter catalytic activity |
| paaZ | Aldehyde dehydrogenase deficiency | Overexpression in mammalian cells |
Uremic Toxicity in Chronic Kidney Disease
Phenylacetate is a uremic toxin that accumulates in chronic kidney disease and contributes to cardiovascular and neurological complications. Impaired catabolism leads to elevated levels, and therapeutic strategies aim to enhance its clearance.
Inherited Metabolic Disorders
Disorders of phenylalanine metabolism, such as phenylketonuria, result in increased phenylacetate production. Phenylacetate is used as a nitrogen scavenger in urea cycle disorders, highlighting its clinical relevance.
Mitochondrial Dysfunction and Metabolic Disease
Gut microbiota-derived lysine phenylacetylation, which intersects with phenylacetate metabolism, impairs mitochondrial function and is alleviated by SIRT3, linking this pathway to metabolic and age-related diseases.
From phenylacetate catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does paaF knockout block phenylacetate catabolism? | CRISPR knockout in E. coli |
| Can a point mutation in paaG alter substrate specificity? | CRISPR point mutation |
| Does overexpression of paaABCDE enhance degradation? | CRISPR overexpression |
| How does PaaX regulate the paa operon? | Knock-in of tagged PaaX |
| What is the role of SIRT3 in phenylacetylation? | SIRT3 knockout mouse |
| Can phenylacetate catabolism be engineered for bioremediation? | CRISPR library screening in Pseudomonas |
How to Study the phenylacetate catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Phenylacetate and intermediates | Quantify pathway flux |
| RNA-seq | Expression of paa genes | Regulation studies |
| Enzyme kinetics | Catalytic activity of paa enzymes | Characterize mutants |
| CRISPR knockout screen | Genes required for growth on phenylacetate | Identify essential genes |
| CRISPR interference | Knockdown of paa genes | Study dose-dependent effects |
| Reporter assays | Promoter activity of paa operon | Regulation by PaaX |
| Isotope tracing | Carbon flux through pathway | Metabolic engineering |
| Protein crystallography | Structure of paa enzymes | Mechanistic insights |
Metabolomics and Flux Analysis
Metabolomics using LC-MS or GC-MS can quantify phenylacetate and its catabolic intermediates, providing a snapshot of pathway activity. Flux analysis with labeled substrates can trace carbon flow through the pathway.
Transcriptomics and Gene Expression
RNA-seq can measure expression of paa genes under different conditions, revealing regulatory mechanisms. This is particularly useful for studying PaaX-mediated repression.
Enzymatic Assays
In vitro enzymatic assays with purified paa enzymes can determine kinetic parameters and substrate specificity. These assays are essential for characterizing point mutations.
CRISPR Screening
Genome-wide CRISPR knockout or interference screens can identify genes required for phenylacetate catabolism in bacteria or mammalian cells, uncovering novel regulators.
How CRISPR Can Be Used to Study GO:0010124 phenylacetate catabolic process
Knockout
CRISPR knockout of paa genes in bacteria such as E. coli can abolish phenylacetate catabolism, allowing researchers to confirm gene essentiality and study pathway flux. For example, paaF knockout prevents activation of phenylacetate, blocking the entire pathway.
Point Mutation
CRISPR point mutations can be introduced into catalytic residues of paa enzymes to dissect their roles. For instance, mutating the active site of paaG can reveal its importance in ring cleavage.
Knock-in
Knock-in of tagged versions of paa proteins (e.g., FLAG or GFP) enables localization and interaction studies. This is useful for understanding the assembly of the paa oxygenase complex.
Overexpression
CRISPR activation (CRISPRa) or plasmid-based overexpression can increase paa gene expression, enhancing phenylacetate degradation. This approach is valuable for metabolic engineering and bioremediation.
How EDITGENE Supports phenylacetate catabolic process Research
Researchers studying phenylacetate catabolic process-related genes often need to determine whether a candidate gene is causally involved in the pathway, and CRISPR-based models provide the most direct way to test this. EDITGENE offers a comprehensive suite of services to generate precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for phenylacetate catabolic process research.
Frequently Asked Questions About phenylacetate catabolic process
What is phenylacetate catabolic process?
It is the breakdown of phenylacetate, an aromatic compound, into central metabolites, as defined by GO:0010124.
What genes are involved in phenylacetate catabolic process?
Key genes include paaA, paaB, paaC, paaD, paaE, paaF, paaG, paaH, paaJ, paaK, paaX, and paaZ, primarily in bacteria.
Which organisms perform phenylacetate catabolism?
Bacteria such as Escherichia coli and Pseudomonas species are well-known for this pathway; gut microbiota also contribute in mammals.
How is phenylacetate catabolic process regulated?
In bacteria, it is regulated by the repressor PaaX, which is inactivated by phenylacetate.
What diseases are associated with phenylacetate catabolism?
Uremic toxicity, inherited metabolic disorders, and mitochondrial dysfunction have been linked to phenylacetate metabolism.
Can CRISPR be used to study phenylacetate catabolic process?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect gene function in this pathway.
What are the end products of phenylacetate catabolism?
The pathway yields acetyl-CoA and succinyl-CoA, which enter the TCA cycle.
Is phenylacetate catabolism important in humans?
Yes, phenylacetate is a uremic toxin and its catabolism affects human health, particularly in kidney disease.
What methods are used to study phenylacetate catabolic process?
Metabolomics, RNA-seq, enzymatic assays, and CRISPR screens are commonly used.
How can I model phenylacetate catabolic process in the lab?
EDITGENE offers CRISPR knockout, point mutation, knock-in, and overexpression services to create tailored cell models.
Conclusion
Phenylacetate catabolic process (GO:0010124) is a fundamental biological pathway with significant implications for microbial metabolism, human health, and disease. Understanding its genes and regulation provides insights into uremic toxicity, metabolic disorders, and potential therapeutic targets. CRISPR-based models are indispensable for advancing this research, and EDITGENE provides the tools to accelerate discovery.
References
- 1. Du W et al.. 2026. Gut microbiota-derived lysine phenylacetylation impairs mitochondrial function and is alleviated by SIRT3.. Cell Metab 38(9):1864-1880.e8 PMID: 42341761
- 2. Díaz E et al.. 2013. Aerobic degradation of aromatic compounds.. Curr Opin Biotechnol 24(3):431-42 PMID: 23122741
- 3. Batshaw ML et al.. 1987. Treatment of urea cycle disorders.. Enzyme 38(1-4):242-50 PMID: 3326732
- 4. Vanholder R et al.. 2005. New insights in uremic toxicity.. Contrib Nephrol 149:315-324 PMID: 15876855
- 5. Klassa S et al.. 2025. Nitrogen Scavengers: History, Clinical Considerations and Future Prospects.. J Inherit Metab Dis 48(6):e70110 PMID: 41163474
- 6. Teufel R et al.. 2010. Bacterial phenylalanine and phenylacetate catabolic pathway revealed.. Proc Natl Acad Sci U S A 107(32):14390-5 PMID: 20660314
- 7. Cook SD. 2019. An Historical Review of Phenylacetic Acid.. Plant Cell Physiol 60(2):243-254 PMID: 30649529
